Browsing by Author "Göker, Erdem"

Now showing items 1-2 of 2

Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

Tatlı, Ali Murat; Yumuk, Perran Fulden; Öz, Büge; Bilici, Ahmet; Gürsoy, Pınar; Göker, Erdem; Sezer, Ahmet; Özet, Ahmet; Demirci, Umut; Bozkurtlar, Emine; Özbudak, İrem Hicran; Nart, Deniz; Canpolat, Tuğba; Akyürek, Nalan; Kılıçkap, Saadettin (Zerbinis Publications, 2021)

Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ...
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Gürsoy, Pınar; Tatlı, Ali Murat; Erdem, Dilek; Göker, Erdem; Çelik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atçı, Muhammed Mustafa; Bayram, Ertuğrul; Akın Telli, Tuğba; Bilgin, Burak; Bilici, Ahmet (Springer, 2023)

Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...